Can Any Provider Prescribe Testosterone for Trans-Masculine Individuals?
Any qualified provider who can prescribe controlled substances and perform appropriate medical monitoring can prescribe testosterone for trans-masculine individuals—specialist referral is not mandatory, though endocrinology consultation is valuable for complex cases.
Provider Qualifications and Scope
The evidence does not restrict testosterone prescribing to specialists only. The 2009 Endocrine Society guidelines 1 recommend that "endocrinologists review with persons treated the onset and time course of physical changes," but this is a suggestion (Grade 2 evidence), not an absolute requirement that only endocrinologists can prescribe. More recent literature 2 confirms that gender-affirming hormone therapy can be provided by various qualified healthcare providers who understand the treatment protocols and monitoring requirements.
What Any Prescribing Provider Must Do:
Pre-Treatment Requirements:
- Confirm persistent gender dysphoria or gender incongruence
- Verify patient has reached age of legal medical consent and can provide informed consent
- Conduct pretreatment screening including: weight, blood pressure, complete blood count, renal and liver function, lipid and glucose metabolism 1
- Assess for contraindications and conditions that increase therapy-associated risks 2
Ongoing Monitoring Protocol: The provider must commit to regular monitoring 1:
- Maintain testosterone levels in physiological normal male range (typically 300-1000 ng/dL)
- Monitor for adverse events including:
- Erythrocytosis (up to 15% develop elevated hematocrit)
- Liver dysfunction (up to 15% have transient enzyme elevations)
- Hypertension
- Excessive weight gain and salt retention
- Lipid changes
- Excessive or cystic acne
- Adverse psychological changes
Expected Physical Changes Timeline
Providers should counsel patients on realistic expectations 1:
First 3 months:
- Cessation of menses
- Increased libido
- Increased facial/body hair
- Increased skin oiliness
- Increased muscle mass
- Fat redistribution
Within first year:
- Voice deepening
- Clitoromegaly
- Possible male pattern hair loss
Recent data 3 shows breast development in trans-feminine patients may extend beyond the traditional 3-year timeline noted in older guidelines, suggesting individual variability is substantial.
Critical Pitfalls to Avoid
Testosterone is NOT contraception 4: Despite menstrual suppression, pregnancy can occur. A 2025 case report documented pregnancy at 35 weeks in a patient on testosterone therapy. Contraception counseling is mandatory.
Fertility preservation discussion must occur before starting therapy 5, 6: Animal models suggest potential reversibility, but clinical data remains limited. Patients should be informed of fertility preservation options upfront.
Avoid oral 17-alkylated testosterone 1: Use parenteral (intramuscular) or transdermal formulations only to prevent serious hepatic toxicity.
Do not use supraphysiological doses 1: Risk increases significantly with excessive dosing.
When to Refer to Endocrinology
While not mandatory, consider specialist referral for:
- Adolescent patients (additional criteria and pubertal suppression considerations)
- Patients with pre-existing endocrine disorders
- Difficulty achieving target testosterone levels
- Significant adverse effects requiring dose adjustment
- Persistently abnormal lab values despite dose modifications
- Patients requesting non-binary or low-dose protocols 5
Practical Prescribing
Standard regimen 7: Testosterone cypionate 200 mg/mL intramuscularly every 2-4 weeks, or transdermal preparations. The intramuscular ester formulation has approximately 8-day half-life and is absorbed slowly from lipid phase, allowing extended dosing intervals.
The provider must establish a monitoring schedule and commit to long-term follow-up, as these patients require ongoing care similar to any patient on chronic hormone replacement therapy 1, 8.